Provectus Pharmaceuticals Inc. To Receive Fifth Medical Device Patent
KNOXVILLE, Tenn., Dec. 22 /PRNewswire-FirstCall/ -- Provectus Pharmaceuticals, Inc. announced today that it has received a notice of allowance for a patent application covering the Company's laser-based technologies for selective destruction of pigmented tissue, with applicability to elimination of moles and pigmented skin cancers, such as melanomas. The notice of allowance from the U.S. Patent and Trademark Office indicates that the application is in condition for issuance and a U.S. patent will be issued within several months. The patent is anticipated to be the Company's sixteenth U.S. patent and the fifth patent for its medical device technologies.
The pending patent covers methods for use of advanced laser technologies in the destruction of pigmented tissue. Additional areas of applicability include selective destruction of hair follicles for hair reduction along with tattoo removal.
"These methods are fundamental to a range of new laser-based medical devices that should dramatically improve the selectivity and effectiveness of treatments for important skin conditions, both in the therapeutic and cosmetic arenas," said Craig Dees, Ph.D., Provectus CEO and co-inventor. "We continue to assemble an attractive portfolio of technologies that are available for licensure to the medical device industry."
Provectus' laser technologies harness the energy of pulsed lasers in a precise manner that minimizes damage to tissue surrounding the targeted treatment area. In addition, these technologies enable the selective destruction of target tissues based on their inherent light absorption.
About Provectus Pharmaceuticals, Inc.
Provectus Pharmaceuticals, Inc. is a pioneering pharmaceutical company actively engaged in the design, development, and marketing of pharmaceutical technologies for the treatment of metastatic melanoma, breast cancer and liver cancer. In addition, Provectus is preparing to begin Phase 2 clinical studies for the Company's topical agent Xantryl(TM), a treatment for psoriasis.
The Company's offices and laboratory are located at 7327 Oak Ridge Highway, Suite A, Knoxville, TN 37931; telephone: 865 769 4011.
For more information, contact the Company at email@example.com or visit the corporate Web site: http://www.pvct.com.
This release and others statements issued or made from time to time by the company or its representatives contain comments that may constitute forward- looking statements. Those include statements regarding the intent, belief or current expectations of the company and members of its management teams, as well as the assumptions on which the statements are based. Prospective investors are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward- looking statements.Provectus Pharmaceuticals, Inc.
CONTACT: Investors: Matt Clawson of Allen & Caron Inc, +1-949-474-4300,firstname.lastname@example.org, for Provectus Pharmaceuticals, Inc.; or PeterCulpepper of Provectus Pharmaceuticals, Inc., +1-865-769-4011,email@example.com
Web site: http://www.pvct.com//